

Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest
and a Waiver under 18 U.S.C. §208(b)(3)

George Macones, M.D., M.S.C.E.

Committee: Reproductive Health Drugs Advisory Committee

Meeting Date: August 29, 2006

I acknowledge that contingent upon public disclosure of the financial interest listed below, related to supplemental new drug application (NDA) 21-945, 17 alpha-hydroxyprogesterone caproate 250 mg/mL injection, sponsored by Adeza Biomedical Corporation for the proposed indication of the prevention of preterm delivery in women with a history of a prior preterm delivery, I am eligible to receive a waiver under 18 U.S.C. §208 (b)(3).

| Type of Interest | Nature | Magnitude |
|-------------------------|---------------|--------------------|
| Related study | Competitor | Less than \$10,001 |

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of this interest the waiver is not valid.

/s/
Signature of SGE

July 3, 2006
Date